Effect of donor hypernatremia on clinical outcomes in pediatric liver transplantation
Taylor Hathaway1, Richard Barnes1, Joel R. Schroering1, Chandrashekhar A. Kubal1, Plamen Mihaylov1, Burcin Ekser1, Kyla Tolliver2, Chaowapong Jarasvaraparn2, Jean P. Molleston2, Richard S. Mangus1.
1Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States; 2Department of Pediatric Gastroenterology, Indiana University School of Medicine, Indianapolis, IN, United States
Background: Donor hypernatremia remains a concern for some transplant centers when appraising the viability of a potential liver graft. This study examines the practice of routinely utilizing donor liver grafts from deceased donors with severe hypernatremia in the pediatric population.
Methods: This is a single-center retrospective review of 154 pediatric liver transplants from 2001-2022. Donor hypernatremia is grouped based on both peak and terminal sodium levels obtained from organ procurement records (normal, <150 mEq/L; moderate, 150-159 mEq/L; severe, ≥160 mEq/L). Outcomes include post-transplant peak alanine aminotransferase and total bilirubin levels, recipient length of hospital stay, early allograft dysfunction, and graft and patient survival at 7 days, 30 days, and 1-year post-transplant.
Results: There were 154 pediatric liver transplants performed during the study period. Of those, 32 donors (21%) were normonatremic, 49 (32%) moderately hypernatremic, and 73 (47%) severely hypernatremic based on peak serum sodium. Just prior to procurement, 96 donors (62%) were normonatremic, 32 (21%) moderately hypernatremic, and 26 (17%) severely hypernatremic. There was a trend towards more early allograft dysfunction with donor hypernatremia (p=0.10). Graphs and scatterplots of post-transplant transaminase levels fail to show a positive association with donor hypernatremia. While graft and patient survival at 7-days and 30-days did not show a statistically significant difference, 1-year patient survival and Kaplan-Meier estimation showed a trend toward lower patient survival with severely hypernatremic donors (p = 0.06). An increased incidence of early allograft dysfunction in recipients from severely hypernatremic donors was also noted (p = 0.10). Kaplan-Meier estimation of 1-year graft survival stratified by terminal serum sodium showed no difference (p = 0.50).
Conclusions: Pediatric liver transplant recipients have similar post-transplant clinical outcomes in the setting of normal or moderately elevated donor serum sodium. There is evidence to suggest that severe elevations in donor serum sodium (≥160 mEq/L) may impact early graft function and recipient survival. Most donors procured by our local organ procurement organization are actively managed to decrease serum sodium prior to procurement with good outcomes.